Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

Lancet Oncology

Volumn 4, Issue 1, 2003, Pages 37-44

  Middleton, Mark R ^a   Margison, Geoffrey P ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 O 4 BROMOTHEYLGUANINE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; 6 O BENZYLGUANINE; ALKYLATING AGENT; ALTRETAMINE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; BISCHLOROETHYLAMINE DERIVATIVE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; FOTEMUSTINE; GUANINE DERIVATIVE; LOMUSTINE; MELPHALAN; METHYLNITROSOUREA; MITOZOLOMIDE; NITROSOUREA; PLATINUM DERIVATIVE; PROCARBAZINE; STREPTOZOCIN; SULFONIC ACID DERIVATIVE; TEMOZOLOMIDE; TETRAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW; BONE MARROW TOXICITY; CANCER; CANCER RESISTANCE; CANCER TISSUE; CLINICAL TRIAL; DNA REPAIR; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0037243405     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)00959-8     Document Type: Review

References (58)

1. DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Cancer: principles and practice of oncology, 6th edn. Philadelphia: Lippincott-Raven, 2001: 405-18.
2. Margison GP, O'Connor PJ. Biological consequences of reactions with DNA: role of specific lesions. In: Cooper CS, Grover PL, (Eds). Handbook of Experimental Pharmacology. Berlin: Springer, 1990: 547-71.
3. Trewick SC, Henshaw TF, Hausinger RP, et al. Oxidative demethylation by Escherichia coli AlkB directly reverts DNA base damage. Nature (in press).
4. Schabel FM Jr. Experimental evaluation of potential anticancer agents: VIII, effects of certain nitrosoureas on intracerebral L1210. Cancer Res 1963; 23: 725-31.
5. Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-Deoxycytidyl],2-N1-deoxyguanosinyl]-ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 1982; 42: 3102-05.
6. Humbert O, Fiumicino S, Aquilina G, et al. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis 1999; 20: 205-14.
7. Ayi TC, Loh KC, Ali RB, Li BFL. Intracellular localisation of human DNA repair enzyme O6-methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res 1992; 52: 6423-30.
8. Yarosh DB, Hurst-Calderone S, Babich MA, Day RS III. Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumour cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base. Cancer Res 1986; 46: 1663-68.
9. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-29.
10. Scudiero DA, Meyer SA, Clatterbuck BE, et al. Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chlorethyinitrosoureas. Cancer Res 1984; 44: 2467-74.
11. D'Atri S, Piccioni D, Castellano A, et al. Chemosensitivity to triazine compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemia patients. Ann Oncol 1995; 6: 389-93.
12. Fujio C, Chang HR, Tsujimura T, et al. Hypersensitivity of human tumour xenografts lacking O6-alkylguanine-DNA alkyltransferase to the anti-tumour agent 1-(4-amino-2-methyl-5-pyridinyl)methyl-3-(2-chloroethyl)-3-nitrosourea. Carcinogenesis 1989; 10: 351-56.
13. Gerson SL, Zborowska E, Norton K, et al. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharm 1993; 45: 483-91.
14. Brennand J, Margison GP. Expression of the E. coli O6-methylguanine-DNA methylphosphotriester methyltransferase gene in mammalian cells. Carcinogenesis 1986; 7: 185-88.
15. Ishizaki K, Tsujimura T, Yawata H, et al. Transfer of the E. coli O6-methylguanine methyltransferase gene into repair-deficient human cells and restoration of cellular resistance to N-methyl-N-nitro-N-nitrosoguanidine. Mutat Res 1986; 166: 135-41.
16. Chen ZP, Yarosh D, Garcia Y, et al. Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999; 26: 104-09.
17. Jaeckle KA, Harmon JE, Townsend JJ, et al. Correlation of tumor O6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 3310-15.
18. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-57.
19. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumour patients treated with carmustine. Cancer Res 1996; 56: 783-88.
20. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Eng J Med 2000; 343: 1350-54.
21. Ma S, Egyhazi S, Ringborg U, Hanson J. Immunohistochemical detection of DNA mismatch repair and O6-methylguanine-DNA methyltransferase expression in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Proc Amer Assoc Cancer Res 2001; 42: Abstr 3484
22. Middleton MR, Lunn JM, Morris C, et al. O6-Methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78: 1199-202.
23. Chen S, Citron M, Spiegel G, Yarosh D. O6-methylguannine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy. Gynaecol Oncol 1994; 52: 172-74.
24. Hengstler JG, Tanner B, Moller L, et al. Activity of O6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. Int J Cancer 1999; 84: 388-95.
25. Mattern J, Eichhorn U, Kaina B, Volm M. O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tmour xenografts. Int J Cancer 1998; 77: 919-22.
26. Chen JM, Zhang YP, Want C, et al. O6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 1992; 13: 1503-07.
27. Wani G, D'Ambrosio SM. Expression of the O6-alkylguanine-DNA alkyltransferase gene is elevated in human breast tumor cells. Anticancer Res 1997; 17: 4311-15.
28. Lee SM, Reid H, Elder RH, et al. Inter and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase in human brain tumors: possible significance in nitrosourea therapy. Carcinogenesis 1996; 17: 637-41.
29. Citron M, Decker R, Chen S, et al. O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. Cancer Res 1994; 54: 4131-34.
30. Isowa G, Ishizaki K, Sadamoto T, et al. O6-methylguanine-DNA methyltransferase activity in human liver tumors. Carcinogenesis 1991; 12: 1313-17.
31. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-97.
32. Harris LC, von-Wronski MA, Venable CC, et al. Changes in O6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts. Carcinogenesis 1996; 17: 219-24.
33. Pieper RO. Understanding and manipulating O6-methylguanine-DNA ethyltransferase expression. Pharm Ther 1997; 74: 285-97.
34. Micetich KC, Futscher B, Koch D, et al. Phase I study of streptozocin and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst 1992; 84: 256-60.
35. Panella TJ, Smith DC, Clifford Schold S, et al. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Camcer Res 1992; 52: 2456-59.
36. Smith DC, Gerson SL, Liu L, et al. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O6-alkylguanine-DNA alkyltransferase. Clin Cancer Res 1996; 2: 1129-34.
37. Lee SM, Margison GP, Woodcock A, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-60.
38. Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51: 619-23.
39. Gander M, Leyvraz S, Decosterd L, et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyguanine-DNA alkyltransferase in blood lymphocytes and in tumours. Ann Oncol 1999; 10: 831-38.
40. Middleton MR, Lee SM, Arance A, et al. O6-Methylguanine formation, repair protein depletion and clinical outcome with a 4-hourly schedule of temozolomide in the treatment of advanced melanoma: results ofa phase II study. Int J Cancer 2000; 88: 469-73.
41. Dolan ME, Morimoto K, Pegg AE. Reduction of O6-alkylguanine DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines. Cancer Res 1985; 45: 6413-17.
42. Dolan ME, Pegg AE, Moschel RC, Grindey GB. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharamacol 1993; 46: 285-90.
43. Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992; 84: 1926-31.
44. Wedge SR, Newlands ES. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Brit J Cancer 1996; 73: 1049-52.
45. Elder RH, Margison GP, Rafferty JA. Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine. Biochem J 1994; 298: 231-35.
46. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressie malignant glioma. J Clin Oncol 2000; 18: 3522-28.
47. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical trial and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000; 6: 3025-31.
48. Spiro TP, Gerson SL, Liu L, et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59: 2402-10.
49. Friedman HS, Kokkinakis DM, Pluda J, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998; 16: 3570-75.
50. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20: 2277-783.
51. Middleton MR, Ranson M, Bowen R, et al. Phase I study of 4-bromothenylguanine (4-BTG) and temozolomide: preliminary results and O6-alkylguanine-DNA alkyltransferase (ATase) depletion. Proc Am Assoc Cancer Res 2000; 41: (Abstr 3878)
52. Fairbairn L, Watson AJ, Rafferty J, et al. O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Haematol 1995; 23: 112-16.
53. Wang CC, Li J, Teo CS, Lee T. The delivery of BCNU to brain tumors. J Control Release 1999; 61: 21-41.
54. Reinhard J, Hull WE, von der Lieth CW, et al. Monosaccharide-linked inhibitors of O6-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships. J Med Chem 2001; 44: 4050-61.
55. Hobin DA, Fairbairn LJ. Genetic chemoprotection with mutant O6-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2002; 2: 1-8.
56. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20: 2388-99.
57. Friedman HS, Pegg AE, Johnson SP, et al. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase, Cancer Chemother Plarm 1999; 43: 80-85.
58. Okamoto R, Takano H, Okamura T, et al. O6-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 2002; 93: 93-102.